GHRP-2

What it is

GHRP-2 is a synthetic hexapeptide that activates the ghrelin receptor, the same target MK-677 and ipamorelin hit, and triggers a pulse of growth hormone from the pituitary.

Among the growth hormone releasing peptides it occupies an unusual position: it is the only one that any regulator has approved for anything. In Japan it is licensed as a diagnostic agent under the name pralmorelin, given as a single dose with serial growth hormone measurements afterwards to establish whether a patient's pituitary can respond.

What that approval does and does not mean

It means the compound reliably raises growth hormone in humans. That is not in dispute, and it is precisely why it works as a diagnostic: a pituitary that will not respond to GHRP-2 is a pituitary with a problem.

It does not mean anyone has shown that raising growth hormone this way, repeatedly, over months, produces a benefit worth having. The approved use is a single administration to answer a question. The use people are interested in is chronic administration to change body composition, and no regulator has approved that because nobody has run the trial.

This is the same distinction the site applies to tesamorelin, which is approved for a condition most readers do not have. An approval is evidence about a specific use.

Where it sits among the secretagogues

• Against ipamorelin: GHRP-2 produces a larger growth hormone pulse and worse selectivity. It raises cortisol and prolactin measurably, where ipamorelin largely does not. That trade is the entire reason ipamorelin exists.
• Against GHRP-6: less appetite stimulation, similar potency. Most people who want the GH without the hunger choose this one over GHRP-6.
• Against MK-677: GHRP-2 is injected and short-acting, producing discrete pulses. MK-677 is oral and lasts a day, producing sustained elevation. Pulsatility is the argument for the injectable.

Practical notes

• The pairing with a GHRH analogue is the convention. CJC-1295 or tesamorelin plus a ghrelin agonist hits two receptors that amplify each other. It is also two unapproved compounds instead of one.
• Tolerance is a real constraint. Continuous receptor stimulation blunts the response. This is why reported protocols cycle rather than run indefinitely, and the cycling pattern is convention rather than data.
• The diagnostic dose is not the practice dose. Reading the Japanese protocol as dosing guidance is a mistake. Those numbers exist to provoke a single measurable pulse under supervision.

Side effects and warning signs

Commonly reported

• Increased appetite, less dramatic than GHRP-6 but present
• Water retention and tingling in the hands
• Raised cortisol and prolactin, more than with ipamorelin and less than with GHRP-6
• Drowsiness after injection

Stop and get medical help

• Any active malignancy, since the point of the compound is to raise GH and therefore IGF-1
• New or worsening numbness in the hands
• Symptoms suggesting rising blood glucose, since GH opposes insulin

Sources

1. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axisreview
2. Sleeve gastrectomy resolves low GHRP-2-stimulated growth hormone levels in obese patientstrial

From the community

Discussion for this compound concentrates in r/Peptides and r/PeptideAdvice.

No threads cached yet.

Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.